Vertex Ventures HC

What Vertex Ventures HC does

Vertex Ventures HC (also operating as Vertex Ventures Healthcare) is a healthcare-focused venture capital firm founded in 2014 and headquartered in Singapore, with an affiliated address in Palo Alto, California. It operates as part of the broader Vertex global VC network, whose parent is Vertex Holdings and whose affiliates span China, Israel, Japan, Southeast Asia and India, the United States, and a growth-stage fund. The firm invests across biopharmaceuticals, medical devices, and digital health, with a stated emphasis on transformative rather than incremental healthcare innovation. Its portfolio comprises 26 companies (17 biotech and 9 medtech), 30 clinical-stage assets, and 3 FDA-cleared products spanning modalities including gene therapy, cell therapy (notably engineered Tregs), radiopharmaceuticals, nucleic acid therapeutics, covalent precision medicines, GPCR-targeted small molecules, implantable devices, and sustained-release drug delivery.

The firm deploys capital primarily through Series B and Series D equity financings, as evidenced by recent rounds in Allay Therapeutics ($57.5M Series D, June 2025), SpyGlass Pharma ($75M Series D, June 2025), and SonoThera ($125M Series B, June 2026). It has realized nine exits via IPO or strategic acquisition, including Bicycle Therapeutics (NASDAQ: BCYC), Boundless Bio, Neumora, and Septerna on the public side, and Ivantis (Alcon), EyeBio (Merck), Twelve (Medtronic), and Visterra (Otsuka) on the M&A side. Portfolio companies are notably led by Nobel laureates Sir Greg Winter (Bicycle Therapeutics co-founder) and Fred Ramsdell (Sonoma Biotherapeutics co-founder, 2025 Nobel Prize in Physiology or Medicine).

Vertex Ventures HC operates a standard institutional VC revenue model: management fees on committed capital (typically 1.5-2.5% annually) supplemented by carried interest (typically ~20%) on exits above a hurdle rate. With approximately $500M in assets under management and a lean 1-10 employee partnership, the firm's economics depend on a relatively small team driving fund performance. Distribution is entirely through direct equity investments into portfolio companies; the firm does not sell products or services to end customers, nor does it maintain traditional go-to-market functions beyond LP fundraising and portfolio company support.

Name

Vertex Ventures HC

Legal name

Vertex Ventures HC

Website

https://vertexventureshc.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Vertex Ventures HC is a Singapore-headquartered healthcare venture capital firm (founded 2014) managing approximately $500M across 26 portfolio companies in biopharmaceuticals, medical devices, and digital health, with a global deal-sourcing network spanning Asia, the Middle East, and North America.

Ownership category

akta.pro rank

Product category

Venture Capital / Healthcare Investment Management

NAICS

Portfolio Management and Investment Advice (523940), Securities, Commodity Contracts, and Other Financial Investments and Related Activities (523)

SIC

Investment Advice (6282)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

akta.pro secondary industries

Late-Stage Venture Capital (Series C+) (FSANAAAC), Corporate Strategic Partnership & Ecosystem Investment Arms (FSANAHAF)

Keywords

• Healthcare venture capital
• Biotech investment fund
• Medical device investing
• Life sciences funding
• Pharmaceutical equity investing

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Fund Management: Standard venture capital revenue model consisting of management fees (typically 1-2% of committed capital) and carried interest (typically 20% of profits above the hurdle rate). Returns generated through portfolio company exits via IPO, M&A, and secondary sales.

Go-to-market motion1 record

Marketing channels3 records

Core offering

Vertex Ventures HC is a healthcare-focused venture capital fund that invests capital in early-to-mid-stage companies developing transformative therapies and medical technologies across biopharmaceuticals, medical devices, and digital health. The firm manages approximately $500M in assets under management across 26+ portfolio companies and supports these companies through key growth and value-creation milestones. It generates returns through management fees on committed capital, carried interest on exits, and portfolio company liquidity events including IPOs and strategic acquisitions.

Product overview

Vertex Ventures HC is a venture capital firm that invests in healthcare companies developing transformative therapies and medical technologies. Rather than offering a unified product platform, the firm provides investment capital and support to its portfolio companies advancing clinical-stage assets across biotechnology (gene therapies, cell therapies, radiopharmaceuticals, nucleic acid therapeutics) and medical technology (implantable devices, drug delivery platforms). The firm manages over $500M across 26+ companies with 30 clinical-stage assets and 3 FDA-cleared products.

Differentiator

Problem solved

Functional benefit

Products and services

• Healthcare Venture Capital Investment Services Investment management and venture capital funding for early-to-mid-stage healthcare companies developing transformative therapies and medical technologies across biopharmaceuticals, medical devices, and digital health. The firm provides capital deployment, strategic guidance, and value-creation support through key growth and clinical milestones, targeting returns via management fees and carried interest from portfolio exits including IPOs and strategic acquisitions.

Quantifiable outcome

• 9 Acquired/IPO exits including Bicycle Therapeutics, Ivantis (acquired by Alcon), EyeBio (acquired by Merck), Twelve (acquired by Medtronic), Visterra (acquired by Otsuka)

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Global Vertex NetworkcoreStrategic or Co-development PartnerVertex Ventures HC is part of Vertex's global network of venture capital funds including affiliates in China (vertexventures.cn), Israel (vertexventures.co.il), Japan (vertexventures.jp), Southeast Asia & India (vertexventures.sg), US (vvus.com), and Growth fund (vertexgrowth.com). This network enables coordinated deal sourcing and portfolio support across regions.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• ARCH Venture Partners: Sector-specialist life sciences and technology venture firm that builds and backs breakthrough science companies from inception through commercialization. Highly comparable in transformative-therapy focus and stage breadth to Vertex Ventures HC.
• Atlas Venture: Early-stage biotech-focused venture firm that builds companies around innovative science. Comparable in sector-specialist, transform-therapeutics focus and stage orientation, though typically earlier-stage than Vertex Ventures HC's mixed Series B/D activity.
• RA Capital Management: Healthcare-focused investment firm combining public and private investing across therapeutics, medtech, and diagnostics. Comparable as a sector-specialist co-investor alongside Vertex Ventures HC in recent rounds (e.g., SonoThera Series B).
• OrbiMed: One of the largest dedicated healthcare venture capital firms globally, investing across biopharma, medtech, and digital health at all stages. Closely comparable in vertical focus and late-stage participation strategy to Vertex Ventures HC.
• 5AM Ventures: Healthcare-focused venture firm investing in early-stage life sciences companies across biotech and medtech. Comparable as a sector-specialist with a similar transformative-therapy thesis and stage profile.
• venBio Partners: Life sciences-focused venture capital firm investing in biopharmaceutical companies at various stages. Comparable as a healthcare-specialist firm with a similar therapeutic-orientation and willingness to participate in Series B/D rounds.

Broad incumbents

• Andreessen Horowitz (a16z Bio): Large generalist VC with a dedicated bio/health fund investing across therapeutics, digital health, and biology platforms. Comparable healthcare investing activity, though a16z operates at much larger AUM and broader scope.
• Bessemer Venture Partners: Multi-stage venture firm with a long-standing healthcare practice investing in biotech, medtech, and healthcare services. Comparable in healthcare deal participation, though broader in sector scope than Vertex Ventures HC.
• New Enterprise Associates (NEA): Large diversified venture firm with a significant healthcare practice spanning biotech, medtech, and digital health. Comparable healthcare investment activity, though NEA operates across multiple sectors and at much larger AUM.

Regional players

• Forbion: European healthcare-dedicated venture capital firm with similar biopharma/medtech focus. Comparable as a sector specialist, though primarily Europe-based rather than Silicon Valley/Asia-Pacific like Vertex Ventures HC.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/vertexventures

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments43 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vertex Ventures HC